|
05/11/2024
|
14:25
|
Director/PDMR Dealings
|
RNS
|
|
04/11/2024
|
10:17
|
Result of General Meeting
|
RNS
|
|
16/10/2024
|
13:37
|
Publication of Prospectus & Notice of GM
|
RNS
|
|
20/09/2024
|
14:24
|
£300,000 Fundraise
|
RNS
|
|
18/06/2024
|
07:00
|
Half-year Report
|
RNS
|
|
17/06/2024
|
07:00
|
Patent Update
|
RNS
|
|
19/03/2024
|
14:39
|
Result of AGM
|
RNS
|
|
01/03/2024
|
07:00
|
Subscription to raise £150,000
|
RNS
|
|
15/01/2024
|
11:30
|
Posting of Annual Report and Notice of AGM
|
RNS
|
|
03/01/2024
|
07:00
|
Results for the period ended 30 September 2023
|
RNS
|
|
18/12/2023
|
07:00
|
NXP001 Update
|
RNS
|
|
23/10/2023
|
07:00
|
Notice of Allowance of NXP002 Patent in Japan
|
RNS
|
|
18/09/2023
|
07:00
|
NXP001 Update
|
RNS
|
|
24/08/2023
|
13:22
|
Result of Annual General Meeting
|
RNS
|
|
31/07/2023
|
14:00
|
Notice of AGM
|
RNS
|
|
26/07/2023
|
14:55
|
Holding(s) in Company
|
RNS
|
|
25/05/2023
|
07:00
|
Change of Auditor
|
RNS
|
|
22/05/2023
|
07:00
|
Unaudited Interim Report
|
RNS
|
|
18/05/2023
|
07:00
|
NXP002 Inflammation and Duration of Action Update
|
RNS
|
|
26/04/2023
|
10:55
|
Holding(s) in Company
|
RNS
|
|
17/04/2023
|
07:00
|
Subscription to raise £70,000 & issue of Warrants
|
RNS
|
|
27/03/2023
|
07:00
|
NXP002 Update
|
RNS
|
|
13/03/2023
|
07:00
|
Change of Accounting Reference Date
|
RNS
|
|
03/01/2023
|
13:37
|
Holding(s) in Company
|
RNS
|
|
20/12/2022
|
13:02
|
Nuformix hoping to 'initiate discussions with major pharma' in 2023
|
EQS Group
|
|
20/12/2022
|
07:00
|
NXP004 Update
|
RNS
|
|
13/12/2022
|
07:00
|
Half-year Report
|
RNS
|
|
05/12/2022
|
07:00
|
Resignation of Auditor
|
RNS
|
|
16/11/2022
|
08:50
|
Holding(s) in Company
|
RNS
|
|
23/09/2022
|
07:00
|
NXP002 Update
|
RNS
|
|
25/08/2022
|
14:39
|
Result of AGM
|
RNS
|
|
19/08/2022
|
08:57
|
Holding(s) in Company
|
RNS
|
|
10/08/2022
|
07:00
|
NXP002 Completion of Tolerability Studies
|
RNS
|
|
01/08/2022
|
12:13
|
Posting of Annual Report and Notice of AGM
|
RNS
|
|
28/07/2022
|
07:01
|
Board Changes
|
RNS
|
|
28/07/2022
|
07:00
|
Annual Results for the year ended 31 March 2022
|
RNS
|
|
05/07/2022
|
07:00
|
NXP002 data to be presented at 2022 ERS Congress
|
RNS
|
|
29/06/2022
|
07:00
|
NXP004 Update
|
RNS
|
|
27/06/2022
|
07:00
|
NXP002 Update
|
RNS
|
|
20/06/2022
|
07:00
|
Holding(s) in Company
|
RNS
|
|
31/05/2022
|
07:00
|
Directorate Change
|
RNS
|
|
30/05/2022
|
07:00
|
Corporate Update
|
RNS
|
|
12/04/2022
|
07:00
|
Second tranche of Lanstead subscription shares
|
RNS
|
|
11/04/2022
|
15:54
|
Holding(s) in Company
|
RNS
|
|
08/04/2022
|
11:21
|
Holding(s) in Company
|
RNS
|
|
07/04/2022
|
15:44
|
Holding(s) in Company
|
RNS
|
|
05/04/2022
|
18:07
|
Holding(s) in Company
|
RNS
|
|
28/03/2022
|
07:00
|
NXP004 Patent
|
RNS
|
|
02/03/2022
|
07:00
|
Appointment of Dr Dan Gooding as Consultant
|
RNS
|
|
01/03/2022
|
07:00
|
Change of Auditor
|
RNS
|